Effects of liraglutide on inducing long-term clinical remission in newly diagnosed type 2 diabetes after intensive treatment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009666

Enrollment

Unknown

Registered

2016-10-27

Start date

2016-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Liraglutide group:Liraglutide

Metformin group:Metformin

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. FBG=11.1mmol/L and/or HbA1c=9.0%; 2. BMI = 24kg/m2; 3. Duration 0-12 months; 4. Not accepted any oral glucose-lowering drugs.

Exclusion criteria

Exclusion criteria: 1. Acute diabetes complications; 2. concurrent infection; 3. Combined liver and kidney impairment; 4. Combined cardiac insufficiency.

Design outcomes

Primary

Measure	Time frame
FPG;2hPG;HbA1c;FC-P;2hC-P;HOMA-ß;	—

Secondary

Measure	Time frame
BMI;Gastrointestinal adverse reactions;	—

Countries

China

Contacts

Public ContactShen Yanjun

Liaocheng City People's Hospital

18663560871@163.com+86 18663560871

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026